SURGE: Supporting UnderRepresented Minorities in Genomics-based Cancer Trial Enrollment (Intervention) (NCT05375643)
🩺 Plain-English Summary (8th-Grade Level)
SURGE aims to increase equity in clinical trial enrollment by addressing barriers to genomic testing, which is increasingly needed to assess precision clinical trial eligibility and access standard precision therapies. The study is an interventional pilot meant primarily to assess the feasibility of the intervention. The intervention is comprised of a patient navigator, text message questionnaire, and informational video.
Who can join: Review the eligibility criteria below.
Location: Dana Farber Cancer Institute — Boston, Massachusetts
Age range: 18 Years
🧪 Interventions in This Study
- SURGE (BEHAVIORAL)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (3 Sites)
- Dana Farber Cancer Institute — Boston, Massachusetts
- Dana-Farber Cancer Institute at St. Elizabeth's Medical Center — Brighton, Massachusetts
- Dana-Farber Cancer Instiute - Merrimack Valley — Methuen, Massachusetts
📞 Contact the Study Coordinator
Phone: (617) 632-6729
Email: nj_mccleary@dfci.harvard.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Gastrointestinal Cancer
- Advancing Nursing Practices in Hospital Oncology Care — New York, New York
- Avatrombopag vs. Placebo for CIT in GI Malignancies — Miami, Florida
- A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005) — New Haven, Connecticut
- Dyadic Sleep Study — Coral Gables, Florida
- EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer. — Cleveland, Ohio
- Intraoperative Imaging of Gastrointestinal Malignancies Using Pafolacianine (CYTALUX™) — Los Angeles, California
Explore by condition: All Gastrointestinal Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.